Perbedaan Profil Lipid Serum Sebelum dan Sesudah Pengobatan Olanzapin pada Pasien Skizofrenik
DAFTAR RUJUKAN
1. Gelder M, Harisson P, Cowen P. Schizophrenia. Shorter Oxford
Textbook of Psychiatry. Edisi ke- Lima.Oxford University Press Inc.
New York. 2006.h.267-306.
2. Hales RE, Yudofsky SC, Gabbard GO. Schizophrenia.The American
Psychiatric Publising Textbook of psychiatry. Edisi ke Lima. 2008.h.132.
3. Andreasen NC. Consept of Schizophrenia: Past, Present, and Future.
Dalam : Weinberger DR, Harisson PJ.Schizophrenia. Edisi ke Tiga.
2011.h.3-8.
4. Sadock BJ, Sadock VA. Kaplan & Sadock’s Synopsis of Psychiatry.
Behavioral Sciences/Clinical Psychiatry. Edisi Kesepuluh. Philadelphia
: Lippincott William & Wilkins. 2005 : h. 467 – 97.
5. Departemen Kesehatan Republik Indonesia. Pedoman Penggolongan
dan Diagnosis Gangguan Jiwa di Indonesia III (PPDGJ III). Jakarta,
1993 : h.105-109.
6. Roohafza H, Khani A, Afsar H,Garakyaraghi, Amirpour, Ghodsi B. Lipid
profile in antipsychotic drug users: A comparative study. ARYA
Atheroscler 2013; 9(3): 198-202.
7. Moghadamnia M. Metabolic effect of Olanzapin medication on weight
gain. Life Science Journal 2013; 10(3).
8. Huang TL, Lu CY. Correlation between Weight Changes and Lipid
Profile Changes in Schizophrenic Patient after Antipsychotics Therapy.
Chang Gung Med J 2007; 30:26-32.
9. Kim BJ, Sohn JW, Park CS, Hahn GH, Koo J, Noh YD, et al. Body
Weight and Plasma Levels of Ghrelin and Leptin during Treatment with
Olanzapine. J Korean Med Sci 2008; 23: 685-90.
10. Tarricone I, Casoria M, Gozzi BF, Grieco D, Menchetti M, Serretti A, et
al. Metabolic risk factor profile associated with use of second
generation antipsychotics: a cross sectional study in a community
mental health centre. BMC Psychiatry 2006, 6:11.
Universitas Sumatera Utara
11. Barnwal A, Oza B, Patel V. Metabolic side effects of antipsychotic
agents: a prospective study in a teaching hospital. NHL Journal of
Medical Sciences. 2012.h.23-26.
12. Nagamine T. Direct metabolic effects of risperidone and olanzapine in
Japanese schizophrenic patients. Neuropsychiatry desease and
treatment 2007 : 3(1) 177-79.
13. Thaker GK. Schizophrenia : Phenotypic Manifestations. Dalam: Sadock
BJ, Sadock VA.Kaplan & Sadock’s Comprehensive Textbook of
Psychiatry. Edisi kesembilan. Vol I. Philadelphia : Lippincott Williams &
Wilkins. 2009. h. 1542 – 47.
14. American Psychiatric Association. Diagnostic and Statistical Manual of
Mental Disorder. Fifth Edition. Arlinton VA. 2013.h.87-122.
15. Marder
SR,
Hurford
IM,
Kammen
DPV.
Second-Generation
Antipsychotics. Dalam: Kaplan & Sadock’s Comprehensive Textbook of
Psychiatry. Edisi kesembilan. Vol II. Philadelphia : Lippincott Williams &
Wilkins. 2009.h.3222-26.
16. Konsensus Penatalaksanaan Gangguan Skizofrenia.Terapi Biologi.
Perhimpunan Dokter Spesialis Kedokteran Jiwa Indonesia.2011.h.1359.
17. Stahl
SM.
Essential
Psychopharmacology
The
Prescriberꞌs
Guide.Olanzapine.Cambridge University Press. New York.h.335-340.
18. Suyono S. Hiperlipidemia. Balai Penerbit FKUI, Jakarta, Edisi Ketiga,
1996. h.714-24.
19. Tsai MC, MD,Chang CM, Huang TL. Changes in High-density
Lipoprotein and Homeostasis Model Assessment of Insulin Resistance
in Medicated Schizophrenic Patients and Healthy Controls. Chang
Gung Med J 2010; 33: 613-8.
20. Teixeira PJR , Rocha FL. Metabolic side effects of antipsychotics and
mood stabilizers. Review Article.2006.h.1-22.
21. Mortimer AM. Symptom rating scales and outcome in schizophrenia.
BJP 2007, 191:s7-s14.
Universitas Sumatera Utara
22. Blacker D. Psychiatric Rating Scale. Dalam : Sadock BJ, Sadock VA
Ruiz P. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry.
Edisi kesembilan. Philadelphia : Lippincott Williams & Wilkins. 2009.
h.1034-7.
23. Kay SR, Flszbeln A, QpJer LA. The Positive and Negative Syndrome
Scale (PANSS) for Schizophrenia. Vol. 13, no. 2,1967.
24. Zong KX, Sweitzer DE, Hamer RM, Lieberman JA. Comparison
Quetiapin and Risperidone in Treatment of Schizophrenia: A
Randomized, Double-Blind, Flexible Dose, 8-Week Study. J clin
Psychiatry 2006; 67: 1093-1103.
25. Dahlan MS. Evidence Based Medicine seri 2. Besar Sampel dan Cara
Pengambilan Sampel untuk Penelitian Kedokteran dan Kesehatan.
Seri Evidence Medicine 2.Edisi ke-3 Jakarta: Salemba Medika; 2010.
26. National Cholesterol Education Program National Heart, Lung, and
Blood Institute National Institutes of Health. Third Report of the
National Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III) Final Report. 2002.h.II-1 – II-60
27. Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy
PM, et al. Metabolomic mapping of atypical antipsychotic effect in
schizophrenia. Molecular Psychiatry (2007) 12, p.934-45.
28. McEvoy J, Baillie RA, Zhu H, Buckley P, Keshavan MS, Nasrallah HA,
et al. Lipidomics reveal early metabolic change in subjects with
schizophrenia: Effects of atypical antipsychotics. PLOS ONE 2013:
vol.8,p.1-12.
Detection,
Evaluatio
Universitas Sumatera Utara
1. Gelder M, Harisson P, Cowen P. Schizophrenia. Shorter Oxford
Textbook of Psychiatry. Edisi ke- Lima.Oxford University Press Inc.
New York. 2006.h.267-306.
2. Hales RE, Yudofsky SC, Gabbard GO. Schizophrenia.The American
Psychiatric Publising Textbook of psychiatry. Edisi ke Lima. 2008.h.132.
3. Andreasen NC. Consept of Schizophrenia: Past, Present, and Future.
Dalam : Weinberger DR, Harisson PJ.Schizophrenia. Edisi ke Tiga.
2011.h.3-8.
4. Sadock BJ, Sadock VA. Kaplan & Sadock’s Synopsis of Psychiatry.
Behavioral Sciences/Clinical Psychiatry. Edisi Kesepuluh. Philadelphia
: Lippincott William & Wilkins. 2005 : h. 467 – 97.
5. Departemen Kesehatan Republik Indonesia. Pedoman Penggolongan
dan Diagnosis Gangguan Jiwa di Indonesia III (PPDGJ III). Jakarta,
1993 : h.105-109.
6. Roohafza H, Khani A, Afsar H,Garakyaraghi, Amirpour, Ghodsi B. Lipid
profile in antipsychotic drug users: A comparative study. ARYA
Atheroscler 2013; 9(3): 198-202.
7. Moghadamnia M. Metabolic effect of Olanzapin medication on weight
gain. Life Science Journal 2013; 10(3).
8. Huang TL, Lu CY. Correlation between Weight Changes and Lipid
Profile Changes in Schizophrenic Patient after Antipsychotics Therapy.
Chang Gung Med J 2007; 30:26-32.
9. Kim BJ, Sohn JW, Park CS, Hahn GH, Koo J, Noh YD, et al. Body
Weight and Plasma Levels of Ghrelin and Leptin during Treatment with
Olanzapine. J Korean Med Sci 2008; 23: 685-90.
10. Tarricone I, Casoria M, Gozzi BF, Grieco D, Menchetti M, Serretti A, et
al. Metabolic risk factor profile associated with use of second
generation antipsychotics: a cross sectional study in a community
mental health centre. BMC Psychiatry 2006, 6:11.
Universitas Sumatera Utara
11. Barnwal A, Oza B, Patel V. Metabolic side effects of antipsychotic
agents: a prospective study in a teaching hospital. NHL Journal of
Medical Sciences. 2012.h.23-26.
12. Nagamine T. Direct metabolic effects of risperidone and olanzapine in
Japanese schizophrenic patients. Neuropsychiatry desease and
treatment 2007 : 3(1) 177-79.
13. Thaker GK. Schizophrenia : Phenotypic Manifestations. Dalam: Sadock
BJ, Sadock VA.Kaplan & Sadock’s Comprehensive Textbook of
Psychiatry. Edisi kesembilan. Vol I. Philadelphia : Lippincott Williams &
Wilkins. 2009. h. 1542 – 47.
14. American Psychiatric Association. Diagnostic and Statistical Manual of
Mental Disorder. Fifth Edition. Arlinton VA. 2013.h.87-122.
15. Marder
SR,
Hurford
IM,
Kammen
DPV.
Second-Generation
Antipsychotics. Dalam: Kaplan & Sadock’s Comprehensive Textbook of
Psychiatry. Edisi kesembilan. Vol II. Philadelphia : Lippincott Williams &
Wilkins. 2009.h.3222-26.
16. Konsensus Penatalaksanaan Gangguan Skizofrenia.Terapi Biologi.
Perhimpunan Dokter Spesialis Kedokteran Jiwa Indonesia.2011.h.1359.
17. Stahl
SM.
Essential
Psychopharmacology
The
Prescriberꞌs
Guide.Olanzapine.Cambridge University Press. New York.h.335-340.
18. Suyono S. Hiperlipidemia. Balai Penerbit FKUI, Jakarta, Edisi Ketiga,
1996. h.714-24.
19. Tsai MC, MD,Chang CM, Huang TL. Changes in High-density
Lipoprotein and Homeostasis Model Assessment of Insulin Resistance
in Medicated Schizophrenic Patients and Healthy Controls. Chang
Gung Med J 2010; 33: 613-8.
20. Teixeira PJR , Rocha FL. Metabolic side effects of antipsychotics and
mood stabilizers. Review Article.2006.h.1-22.
21. Mortimer AM. Symptom rating scales and outcome in schizophrenia.
BJP 2007, 191:s7-s14.
Universitas Sumatera Utara
22. Blacker D. Psychiatric Rating Scale. Dalam : Sadock BJ, Sadock VA
Ruiz P. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry.
Edisi kesembilan. Philadelphia : Lippincott Williams & Wilkins. 2009.
h.1034-7.
23. Kay SR, Flszbeln A, QpJer LA. The Positive and Negative Syndrome
Scale (PANSS) for Schizophrenia. Vol. 13, no. 2,1967.
24. Zong KX, Sweitzer DE, Hamer RM, Lieberman JA. Comparison
Quetiapin and Risperidone in Treatment of Schizophrenia: A
Randomized, Double-Blind, Flexible Dose, 8-Week Study. J clin
Psychiatry 2006; 67: 1093-1103.
25. Dahlan MS. Evidence Based Medicine seri 2. Besar Sampel dan Cara
Pengambilan Sampel untuk Penelitian Kedokteran dan Kesehatan.
Seri Evidence Medicine 2.Edisi ke-3 Jakarta: Salemba Medika; 2010.
26. National Cholesterol Education Program National Heart, Lung, and
Blood Institute National Institutes of Health. Third Report of the
National Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III) Final Report. 2002.h.II-1 – II-60
27. Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy
PM, et al. Metabolomic mapping of atypical antipsychotic effect in
schizophrenia. Molecular Psychiatry (2007) 12, p.934-45.
28. McEvoy J, Baillie RA, Zhu H, Buckley P, Keshavan MS, Nasrallah HA,
et al. Lipidomics reveal early metabolic change in subjects with
schizophrenia: Effects of atypical antipsychotics. PLOS ONE 2013:
vol.8,p.1-12.
Detection,
Evaluatio
Universitas Sumatera Utara